Immunex Enbrel Building Sales Force For Psoriatic Arthritis Approval
Executive Summary
Immunex is building its first internal Enbrel sales force in preparation for etanercept's sBLA approval for psoriatic arthritis, Commercial Operations General Manager Mark Booth announced Aug. 20 during the company's R&D update in Seattle.
You may also be interested in...
Immunex Enbrel Psoriatic Arthritis 12-Month Data To Follow sBLA Approval
Immunex plans to submit 12-month, open-label Enbrel data in psoriatic arthritis patients following FDA's Jan. 16 approval of etanercept for the supplemental indication
Immunex Enbrel Psoriatic Arthritis 12-Month Data To Follow sBLA Approval
Immunex plans to submit 12-month, open-label Enbrel data in psoriatic arthritis patients following FDA's Jan. 16 approval of etanercept for the supplemental indication
Amgen Enbrel Projections Include 3-Month Cushion For Immunex Plant
Amgen's financial forecasts for the Immunex acquisition include a three-month cushion on the start-up date for a new production plant for Enbrel.